NBDF/LinkedIn
Sep 11, 2025, 13:37
Marstacimab Shows 93% Reduction in Treated Bleeds in its Phase 3 Trial
National Bleeding Disorders Foundation shared on LinkedIn:
”Promising news for the hemophilia community!
Pfizer’s HYMPAVZI™ (marstacimab-hncq) shows a 93% reduction in treated bleeds in its Phase 3 trial for people with hemophilia A or B with inhibitors.”
Learn more here.
Stay updated on the emerging in the field of hemophilia with Hemostasis Today.
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question
-
Oct 20, 2026, 04:04Sadia Kamal: Honored to Receive the Outstanding Abstract Award at the 20th Midwest Platelet Conference
-
Oct 20, 2026, 04:03Yu-Hsuan Chen: One Antibody, Two Diseases from FcRn Biology to Clinical Translation
-
Oct 20, 2026, 03:49Domenico Simone Castiello: Rethinking Prolonged DAPT in Multivessel PCI – Insights from the DAPT-MVD Trial
-
Oct 20, 2026, 03:37Rucha Patil: Scaling POC Diagnostics for Haemophilia A and VWD Across India
-
Oct 20, 2026, 03:31Zena Vexler: Targeting Neutrophil Elastase and NETosis to Mitigate Infection-Triggered Childhood Stroke